Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 10/20 | 0.43 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032416 | 1.00 | KIF11 (0.50) | KIF11HRH4TK2TK1ALDH1A1 | |
| SCHEMBL22708323 | 0.93 | KIF11 (0.53) | KIF11HRH4TK2TK1ALDH1A1 | |
| SCHEMBL29824618 | 0.85 | KIF11 (0.57) | KIF11HRH4TK2TK1ALDH1A1 | |
| SCHEMBL11700053 | 0.81 | KIF11 (0.49) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL31203248 | 0.81 | PLA2G2A (0.39) | KIF11HRH4TK2DUTCHRM2 | |
| SCHEMBL6869145 | 0.81 | ALDH1A1 (0.36) | TK2ALDH1A1USP2HPGDTDP1 | |
| SCHEMBL26305099 | 0.80 | CTSK (0.40) | KIF11TK1ALDH1A1USP2LPAR3 | |
| SCHEMBL25260772 | 0.80 | PLA2G2A (0.38) | KIF11HRH4TK2DUTCHRM2 | |
| SCHEMBL6554439 | 0.80 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL25300207 | 0.79 | PLA2G2A (0.43) | KIF11TK2ALDH1A1USP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109906230-B | Endosomolytic agent for gene therapy | UCB生物制药有限责任公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3519423-B1 | ENDOSOMOLYTIC AGENTS FOR GENE THERAPY | UCB Biopharma SRL (BE) | 2021-04-07 | — | — | EP | disclosed |
| EP-3519423-B1 | ENDOSOMOLYTIC AGENTS FOR GENE THERAPY | UCB Biopharma SRL (BE) | 2021-04-07 | — | — | EP | disclosed |
| US-10842884-B2 | Endosomolytic agents for gene therapy | UCB Biopharma SRL (BE) | 2020-11-24 | — | — | US | disclosed |
| US-10842884-B2 | Endosomolytic agents for gene therapy | UCB Biopharma SRL (BE) | 2020-11-24 | — | — | US | disclosed |
| US-20190298859-A1 | Endosomolytic Agents for Gene Therapy | UCB BIOPHARMA SRL (UCB BIOPHARMA SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2019-10-03 | — | — | US | disclosed |
| US-20190298859-A1 | Endosomolytic Agents for Gene Therapy | UCB BIOPHARMA SRL (UCB BIOPHARMA SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2019-10-03 | — | — | US | disclosed |
| CN-109906230-A | Endosomolytic agent for gene therapy | UCB生物制药私人有限公司 | 2019-06-18 | — | — | CN | disclosed |
| WO-2018060280-A1 | ENDOSOMOLYTIC AGENTS FOR GENE THERAPY | UCB BIOPHARMA SPRL (BE) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842884-B2 | Endosomolytic agents for gene therapy | YARS1, ARSA, RPS6 | KIF11 1976/4885HRH4 1596/4885TK2 408/4885 |
| US-20190298859-A1 | Endosomolytic Agents for Gene Therapy | YARS1, ARSA, RPS6 | KIF11 1976/4885HRH4 1596/4885TK2 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.